SRSR -A $400 investment turns into $170,800

SRSR continues to charge ahead closing up another 5% today at $.178, up from our post at $.11. The stock just can't be stopped. This is one of those penny stocks that will be talked about and compared to for years to come. Several years back SRSR was trading in the triple zero range and has since mounted a deliberate and consistent rally to current levels.

SRSR represents what all penny stock traders are looking to get when they purchase a penny stock. A $400 investment in SRSR at $.0004 would now be worth, as of todays close, $170,800. How is that for a ROI?

BIEL - More Gains Today

BIEL continued its bullish rampage today, following the big board surge, and climbed to an all-time high of $.0665 well off it low of $.0011 in Early May. The action today could have very well been the top of the over all move in the stock.

Below is the news from Wednesday:

BioElectronics to Hold Conference Call to Discuss Clinical Data Results and Status of FDA Filings

Dr. David G. Genecov to Present Results of a Clinical Study and Management Team to Provide Update on Corporate Activities, Other Clinical Studies, Distribution and FDA Filings

FREDERICK, MD, Jul 22, 2009 (MARKETWIRE via COMTEX) -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced a conference call will be held at 11AM (EDT), Tuesday, July 28th to discuss the results of a clinical study recently completed under the direction of David G. Genecov, M.D. FACS FAAP and Joel Brook, DPM, MS, FACFAS. The management team will also provide its stakeholders with an update on corporate activities and information on the status of FDA filings.

"We are very excited about the completion of this important study and we look forward to discussing the results. We thank Dr. Genecov and Dr. Brook and the many other physician primary investigators who are working diligently to determine the efficacy and safety of our patented, portable PEMF technology," commented Andrew Whelan, CEO of BioElectronics. "On our last call we had over 550 investors attempt to access the call, which overwhelmed the capacity of the conference bridge. We have ensured that all who attempt to access next week's call will be able to hear Dr. Genecov and the management team provide the latest information on the exciting developments at our company. We will also be available to answer your questions after the formal presentations have been completed."

To access the call, dial (888) 296-4217 five to ten minutes before the start time. You may be asked for passcode 4461002. There will be a replay of the call available for seven days, which can be accessed by dialing (888)203-1112 and entering passcode 4461002. Those seeking to access the call or recording from outside the U.S. should contract the Company for dial instructions.

About BioElectronics Corporation

BioElectronics Corporation is the maker of ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.

Read more about Dr. Genecov at the following link: http://www.genecovplasticsurgery.com/images/CV_genecov.pdf

Read more about Dr. Brook at the flowing link: http://www.dallaspodiatryworks.com/about.html

For media enquiries, please contact:
Joe Noel
(925) 922-2560

BIEL - Another Pennystockguru Winner

WE alerted BIEL in the middle of June at $.005 after we noticed some increase volume. The post is below. Since that time BIEL has mounted a furious rally and closed today at $.043. A $500 purchase at our alert would have netted you $4,000+ at today's close. Not bad for a few weeks worth of doing nothing.

BIEL has fed the investment community a steady diet of press releases. If you are positioned in BIEL at this stage the trend is up. IF you have yet to hop on board, you might not want to chase, as the party will end at some point. No sense getting in near the top.

BIEL still could have some very impressive upside left. Possibly the $.10 range. It will be fun to watch the next few sessions to see if the momentum continues.


Our BIEL alert post is below:

BIEL - BioElectronics Corp - Volume/Price Breakout
BIEL popped 54% today on 226+ Million shares traded. That is some very impressive money volume. We've seen similar money volume in OTCBB land. One stock in particular started off its run with similar volume - SPNG. We all know where that has ended up.

CEO letters and Press Releases might try and tell you one thing to get you to buy a stock, but money flow tells you something else. When you get $100's of thousands pounding the ask all day you can't question press, news, or anything else - just follow the money... plain and simple. If people are buying hop on the train. If they are selling stay away. It sounds pretty simple. In this case it is. Sometimes its not as easy to see. If the money keeps flowing BIEL's way than the price will continue to pop.

OXBO - Employing O2 and Preserving Life

OXBO moved ahead almost 20% on Monday with a very positive news release (pasted below for your convenience) OXBO looks to be strengthening, up almost 100% in the last 30 days, and poised to test its 2008 highs.

We are in our early stages of researching this company. This could be a medium term play at $.495. This is another stock to keep on your watch list.




Oxygen Biotherapeutics, Inc. Announces Closing of Offer to Acquire Warrants

DURHAM, N.C., July 20, 2009 /PRNewswire-FirstCall via COMTEX/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has closed its proposed acquisition of outstanding common stock purchase warrants.

The company acquired and cancelled 52.2 million common stock purchase warrants with an exercise price of $0.247 per share and an additional 18.7 million warrants with an exercise price of $0.245 per share, or a total of 70.9 million warrants. Prior to the transaction there were 121 million warrants outstanding, so the transaction reduces that number to 49.1 million common stock purchase warrants now outstanding. In exchange for the cancelled warrants the company issued to the holders 35.5 million shares of restricted common stock and paid to them $2.8 million in cash.

"The closing of the new financing by the Vatea Fund and the exchange of the warrants marks an enormous leap towards positioning our company for attracting and obtaining future financings that are necessary to support our product development," said Chris Stern, Oxygen Biotherapeutics, Inc. chairman and CEO. "We are glad to have a financing arrangement in place with Vatea Fund that provides the means, after achieving specific milestones, to finance our future growth and development plans. We have significantly improved our working capital position which will enable us to advance the product development programs we have in place and consider a move to a major stock exchange."

The securities purchase agreement with Vatea Fund, assuming all milestones are achieved in a timely manner, provides for Vatea Fund to purchase an additional 60 million shares of the company's stock for a total purchase of 80 million shares for $20 million in cash.

For additional comments by Chris Stern on the investment by Vatea Fund, please see his latest blog and the video posted on the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release and the video referenced in this news release, which is posted on the company website, contain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to use of the money received from Vatea Fund and steps to move the company stock listing to a major exchange. Actual events or results may differ from Oxygen Biotherapeutics' expectations. There can be no assurance that the funds received will be sufficient for the company's growth and development plans or that the company will be successful in moving the stock listing to a major exchange. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics' business can be found in the company's public report filings with the Securities and Exchange Commission, which are available on the SEC website at www.sec.gov and through our website at www.oxybiomed.com. Oxygen Biotherapeutics disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Oxygen Biotherapeutics, Inc.

MSTF - Put It On Your Watch List

MSTF has come out with several press releases recently that might indicate this stock will see active trade the next few weeks.

Just last week this stock was stuck with no bid and shareholders were unable to unload their positions. Today, at last check, four market makers are willing to take sales at .0001 while a six market makers where looking to take buys at $.0002.

Let's see if the bid firms over the next few sessions.

Today's news is below:

Monarch Staffing, Inc. (MSTF.PK) Awarded New Contract With the California Department of Corrections and Rehabilitation -- Continues to Expand Service Offerings Market Wire    "US Press Releases "
SAN JUAN CAPISTRANO, CA -- (MARKET WIRE) -- 07/20/09 -- Monarch Staffing, Inc. (PINKSHEETS: MSTF), and its wholly owned subsidiary Drug Consultants, Inc. ("DCI"), a provider of healthcare staffing services, announced the award of a new contract with the California Department of Corrections and Rehabilitation ("CDCR").

The contract is for Occupational Therapy Services at the CDCR and expires June 30, 2010 .

"We are extremely pleased with the bid and award process with the CDCR. Our new Occupational Therapy Services Contract coupled with other recent contract awards will allow us to continue to diversify our staffing services provided to the State of California and continue to facilitate the growth the Company is experiencing," commented David Walters , Chairman.

DCI furnishes personnel to perform a range of pharmacy, nursing and other healthcare staffing services in support of the operations of government and commercial facilities, including its largest client, the California Department of Corrections and Rehabilitation . DCI has experience in providing its services in rural areas of California where many state facilities are located and healthcare professionals are not readily available.

This Press Release contains or incorporates by reference "forward-looking statements" including certain information with respect to plans and strategies of Monarch Staffing Inc. For this purpose, any statements contained herein or incorporated herein by references that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "suggests," "anticipates," "plans," "expects," and similar expressions are intended to identify forward-looking statements. There are a number of events or actual results of Monarch Staffing operations that could differ materially from those indicated by such forward-looking statements.

Contact Investor Relations: David Walters Chairman 949-373-7282 Email Contact www.monarchstaffinginc.com

SRSR - A Stock That Keeps Going and Going....

SRSR epitomizes a stock we all long for. A stock that continues to reach new hieghts and soar higher on a daily basis. With almost 3/4 of a billion shares outstanding SRSR closed at $.117 today, within a $.01 of its 52 week high.

This stock will just not give up. SRSR currently has an $86+ million market cap per Pink Sheets.com. It will be interesting to see how much more upside is left.

IJJP - The Billion Dollar Penny Stock

A penny stock potentially worth $4.6 billion dollars closed trading today at $.10. This is an amazing story that will continue to unfold.

IJJP has been flying under many traders radars for several months, until recently. On Monday the company filed a 15-12G, which for a shell stock is a sign that the shell is about to undergo a reverse merger. In this case VR Holdings is reverse merging into IJJP and bringing with it a claim to a $4.6 billion lawsuit.


The chart above shows some fairly impressive accumulation. The company expects IJJP to trade around $1 until the lawsuit is settled, at which time shareholders can expect a $12 - $14 per share pay day.

Once the word starts to spread about this stock it could quickly hit the $1 range. As the article below discusses, the stock will move higher as the probabilities of a favorable outcome increase or lower if chances of a $4.6 billion payout are reduced.

Either way being able to buy something at $.10, $.20, or even a $1, when in reality it is likely worth $12-$14 could bring out many people willing to take a chance on a huge payday. The reward, at this point, seems to far outweigh the risk.

This will be a stock to watch for the foreseeable future. Its a unique merger play that could equate to a huge payday to the tune of 1200% or more from today's close.

The news article that brought most of this information to light is pasted below for your convenience:

http://www.investmentnews.com/article/20090405/REG/904039943